Cellectis S.A. (CLLS) vs Cardiff Oncology, Inc. (CRDF)
Cellectis S.A. and Cardiff Oncology, Inc. are both Biotechnology companies. Cellectis S.A. and Cardiff Oncology, Inc. are of similar size ($103.4M and $99.6M). Cellectis S.A. grew revenue faster over the last twelve months: 0.61% against −6.79%. Cellectis S.A. has the higher net margin (−102.3% vs −7,889.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Cellectis S.A. leads on 9 and Cardiff Oncology, Inc. on 7.
Valuation
Profitability
| Metric | CLLS | CRDF | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (90.88%) | (8,320.08%) | 0.00% |
| Net margin | (102.34%) | (7,888.98%) | 0.00% |
| Free cash flow margin | (68.63%) | (8,059.45%) | 0.00% |
| Return on equity | (94.54%) | (94.14%) | (57.72%) |
| Return on assets | (21.02%) | (70.89%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack